Pentoxifylline and vitamin E treatment for prevention of radiation-induced side-effects in women with breast cancer: a phase two, double-blind, placebo-controlled randomised clinical trial (Ptx-5)
| Autor: | Fredrika Killander, Charlotta Jönsson, Peter Höglund, Per-Uno Malmström, Elisabeth Kjellén, Marie Magnusson, Karin Johansson, Anna Weddig |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Cancer Research
medicine.medical_specialty medicine.medical_treatment Breast Neoplasms Radiation-Protective Agents Placebo Gastroenterology Antioxidants Pentoxifylline law.invention Breast cancer Randomized controlled trial Double-Blind Method law Internal medicine medicine Humans Vitamin E Adverse effect Radiation Injuries Aged Sweden business.industry Radiotherapy Dosage Middle Aged medicine.disease Surgery Clinical trial Treatment Outcome Oncology Drug Therapy Combination Female Radiotherapy Adjuvant Breast disease business medicine.drug |
| Zdroj: | European journal of cancer (Oxford, England : 1990). 45(14) |
| ISSN: | 1879-0852 |
| Popis: | BACKGROUND: A previous study has shown that pentoxifylline in combination with vitamin E can reverse radiation-induced fibrosis. The aim of the present study is to investigate if the same drugs could prevent radiation-induced side-effects in women with breast cancer. PATIENTS AND METHODS: A randomised, placebo-controlled, double-blind, parallel group trial was performed. Women with breast cancer were treated for 12months with 400mg pentoxifylline t.i.d. or placebo, in combination with 100mg vitamin E t.i.d., starting 1-3months after the completion of radiotherapy. The primary end-point was passive abduction of the shoulder, and the secondary end-point was difference in arm volumes. The trial is registered on the ISRCTN.org website, number ISRCTN39143623. RESULTS: 83 patients were included in the study; 42 in the pentoxifylline+vitamin E group and 41 in the placebo+vitamin E group. Both treatments were generally well tolerated. Seven patients were withdrawn from the treatment due to disease progression; four in the pentoxifylline group and three in the placebo group. At inclusion, patients had impaired passive abduction of the shoulder. During treatment, both the groups improved significantly. Median improvement from baseline was 3.7 degrees (p=0.0035) on pentoxifylline and was 9.4 degrees (p=0.0041) in the placebo group, but no difference between the groups was detected (p=0.20). Arm volumes increased over time in the placebo group (1.04%), but not on pentoxifylline (0.50%), and differed significantly between the groups (p=0.0172). CONCLUSIONS: The combination of pentoxifylline and vitamin E was safe and may be used for the prevention of some radiation-induced side-effects. (Less) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect